Sign In
Buy GLP
$48.46
-0.170 (-0.350%)
At Close: Jul 29, 2026
Hims & Hers' Fall From Grace Is Warranted - Still No Margin Of Safety
11:47am, Monday, 03'rd Mar 2025
HIMS' steep correction is well warranted, given the expensive valuations and the headwinds from the now available FDA-approved GLP-1 therapies. However, we believe that the end of GLP-1 shortage is a
Global Partners LP Files 2024 Annual Report on Form 10-K
04:10pm, Friday, 28'th Feb 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) today announced that its Annual Report on Form 10-K for the year ended December 31, 2024, was filed with the U.S. Securities and Exchang
Madrigal Pharmaceuticals: Rezdiffra First-Mover Advantage Gains Traction (Upgrade)
02:29pm, Friday, 28'th Feb 2025
Madrigal Pharmaceuticals, Inc.'s Rezdiffra had a strong launch with $103.3M in Q4 sales and solid liquidity, but GLP-1 competition from Novo and Lilly poses significant future challenges. Madrigal's P
Global Partners LP Common Units (GLP) Q4 2024 Earnings Call Transcript
11:22am, Friday, 28'th Feb 2025
Global Partners LP Common Units (NYSE:GLP ) Q4 2024 Earnings Conference Call February 28, 2025 10:00 AM ET Company Participants Sean Geary - CLO & Secretary Eric Slifka - President & CEO Gregory Hanso
This Could Be the Best GLP-1 Stock to Buy in 2025
08:45am, Friday, 28'th Feb 2025
The GLP-1 weight loss market is a massive one, with some analysts expecting it to be worth around $200 billion by 2031. Hype around weight loss drugs isn't new, but when people are losing more than 20
Global Partners Reports Fourth-Quarter and Full-Year 2024 Financial Results
08:00am, Friday, 28'th Feb 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (“Global” or the “Partnership”) today reported financial results for the fourth quarter and full year ended December 31, 2024. C
Viking Therapeutics: Could GLP-1 Maker Be Acquired Pre-Approval?
07:50am, Wednesday, 26'th Feb 2025
The GLP-1 industry is currently an oligopoly ruled by two pharmaceutical giants, Novo Nordisk A/S NYSE: NVO, maker of semaglutide under the Ozempic and Wegovy name brands, and Eli Lilly & Co. NYSE: L
Wellgistics Expands Healthcare Ecosystem with Tollo Health Agreement, Targeting Multi-Billion Dollar GLP-1 and Long COVID Market
07:40am, Wednesday, 26'th Feb 2025
Tampa, Florida, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Wellgistics Health, Inc. (NASDAQ: WGRX, the "Company"), a holding company for various existing and planned strategic businesses centered around health
Hims & Hers Health: Focus On The Future, Not GLP-1s
02:22pm, Tuesday, 25'th Feb 2025
Hims & Hers Health, Inc. reported strong growth, with Q4 sales up $80 million sequentially, yet HIMS stock fell due to GLP-1 business confusion. The online health and wellness platform guided to $2.3
Hims & Hers: Capitalizing On The GLP-1 Rush Before The Window Closes (Rating Upgrade)
06:47am, Tuesday, 25'th Feb 2025
I expect price sensitive consumers to flood the market for compounded GLP-1 drugs before the 60-day FDA grace period for semaglutide compounders. HIMS projects $725M in GLP-1 weight loss revenue for 2
Hims & Hers shares tumble 18% as margin miss adds to concerns about GLP-1 business
04:43pm, Monday, 24'th Feb 2025
Hims & Hers Health reported fourth-quarter results on Monday that beat analysts' expectations, but the stock sank in extended trading. The company's margin of
Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm
08:00am, Monday, 24'th Feb 2025
5 th study arm in 12-week Phase 1b Study receives lead clinical site approval Kelowna, British Columbia – February 24, 2025 – TheNewswire - Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the
Hims & Hers Declines - How The GLP-1 Market Shift Affects Growth
01:45am, Monday, 24'th Feb 2025
Hims & Hers Health stock dropped 25% after the FDA announced the end of the semaglutide shortage, impacting Hims' weight loss services revenue. Hims plans to launch a generic version of liraglutide, b
3 Solid Options Amid Refining & Marketing MLP Industry Tumult
10:15am, Friday, 21'st Feb 2025
Following a careful analysis of the Zacks Oil and Gas - Refining & Marketing MLP industry, we advise focusing on companies like TRGP, GLP and CAPL.
– SL-325 is a high-affinity DR3 blocking antibody being developed for the treatment of inflammatory bowel disease (IBD); No evidence of toxicity or residual agonism observed in non-human primate t
